Novartis' Afinitor fails in late-stage liver cancer study

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis' (NVS) Afinitor drug failed to extend the survival of patients with advanced liver cancer vs a placebo in a Phase III trial.

However, Novartis intends to continue to study Afinitor (also known as everolimus) for use in treating other cancers, including for gastrointestinal, lung and breast tumors.

Afinitor is already approved for some cancers such as advanced renal cell and pancreatic tumors. (PR)